H.C. Wainwright analyst Andres Y. Maldonado reiterated a Buy rating on Scholar Rock Holding (SRRK – Research Report) today and set a price target of $30.00. The company’s shares closed yesterday at $8.59.
According to TipRanks, Y. Maldonado is ranked #6545 out of 8017 analysts.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Scholar Rock Holding with a $30.00 average price target.
See Insiders’ Hot Stocks on TipRanks >>
Based on Scholar Rock Holding’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $44 million. In comparison, last year the company earned a revenue of $4.6 million and had a GAAP net loss of $30.71 million
Based on the recent corporate insider activity of 22 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SRRK in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Scholar Rock Holding Corp. is a biopharmaceutical company, which engages in the development and discovery of innovative medicines. The company offers proprietary platform which designed to discover and develop monoclonal antibodies that have a high degree of specificity to achieve selective modulation of growth factor signaling. Its product candidate includes SRK-015 and SRK-181. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.
Read More on SRRK: